Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets

The Company Intends to Appeal the Delisting Determination

NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announces that it has received a staff determination letter from the Nasdaq Stock Market, LLC ("Nasdaq"), informing the Company that Nasdaq determined to suspend trading and delist the Company's common stock from Nasdaq. At the open of trading on Thursday, May 22, 2025, Petros' securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the ticker "PTPI".

Fady Boctor, Petros' President and Chief Commercial Officer, commented, "We are disappointed with the delisting determination and we plan to appeal. With over $10 million in cash currently, we remain firmly committed to advancing our business plan and increasing stockholder value."

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. is committed to the goal of becoming a leading innovator in the emerging $38 billion self-care market by providing expanded access to key prescription pharmaceuticals as OTC treatment options. The Company is currently developing a proprietary SaaS platform and a proprietary SaMD web application designed to assist pharmaceutical companies in meeting FDA standards to assist in the Rx-to-OTC switch.

Contacts

Investors: CORE IR [email protected]

Media: Jules Abraham CORE IR 917-885-7378 [email protected]

SOURCE: Petros Pharmaceuticals, Inc.

View the original

press release

on ACCESS Newswire